Company Overview: TGTX

Upcoming Projects (TGTX)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (TGTX)

Another View: Discussing TG Therapeutics' Umbralisib and the potential of Pi3K pathway in treating CLL with a doctor in community practice
Ticker: TGTX
Executed On: Aug 27, 2018 at 04:30 PM EDT
Discussing TG Therapeutics' Umbralisib and the potential of Pi3K pathway in treating CLL with a doctor in community practice
Ticker: TGTX
Executed On: Aug 16, 2018 at 11:00 AM EDT
A discussion on TG Therapeutics' Umbralisib and the potential of Pi3K pathway in treating CLL
Ticker: TGTX
Executed On: Aug 03, 2018 at 01:00 PM EDT

Expired Projects (TGTX)

Discussing TGTX's Umbralisib UNITY-NHL Trial In wake of Rolling NDA Submission in Marginal Zone Lymphoma/Follicular Lymphoma
Tickers: TGTX, BMY, BAYRY
Execute By: Apr 03, 2020

Upcoming & Overdue Catalysts (TGTX)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (TGTX)

TG Therapeutics plans to present top-line overall response rate results from their UNITY-CLL Phase 3 trial in both front line and relapsed or refractory CLL in 2018
Ticker: TGTX
Occurred on: Sep 25, 2018
IPI-549 Combination Dose-Escalation Expected to Complete 2H 2017
Ticker: TGTX
Occurred on: Jan 08, 2018
Interim Data from Phase 2b of UNITY-DLBCL expected 2H 2017
Ticker: TGTX
Occurred on: Aug 10, 2017
UNITY-CLL interim analysis of single agent arms expected 2H 2017
Ticker: TGTX
Occurred on: May 23, 2017
Data from Phase 2 MS trial expected to be presented at a major medical meeting in the first half of 2017
Ticker: TGTX
Occurred on: Apr 28, 2017
Phase 3 top-line data of TG-1101 (Ublituximab) and Imbruvica (GENUINE trial) for Chronic Lymphocytic Leukemia due first half 2017
Ticker: TGTX
Occurred on: Mar 06, 2017
TG Therapeutics, Inc. Announces Publication of Clinical Data from the Phase 1/2 Trial of TG-1101 (ublituximab) Monotherapy in the British Journal of Haematology
Ticker: TGTX
Occurred on: Feb 21, 2017
TG Therapeutics (TGTX) Completes Enrollment for Part 1 of Phase 2 Study of TG-1101 in Relapsing Forms of Multiple Sclerosis (RMS)
Ticker: TGTX
Occurred on: Jan 11, 2017
TG Therapeutics (TGTX) Announces Orphan Drug Designation for the Combination of TG-1101 and TGR-1202 for Treatment of Chronic Lymphocytic Leukemia
Ticker: TGTX
Occurred on: Jan 09, 2017
TG Therapeutics (TGTX) Announces Publication of Clinical Data from the Phase 2 Trial of TG-1101 (ublituximab) in Combination with Ibrutinib in the British Journal of Haematology
Ticker: TGTX
Occurred on: Dec 16, 2016
TG Therapeutics (TGTX) Announces Positive DSMB Recommendation for Continuation of the UNITY-CLL Phase 3 Trial
Ticker: TGTX
Occurred on: Nov 22, 2016
TG Therapeutics (TGTX) Amends the GENUINE Phase 3 Clinical Trial to Accelerate Study Completion by Revising Primary Endpoint to Overall Response Rate
Ticker: TGTX
Occurred on: Oct 13, 2016
Data from a Phase Ib Clinical Trial of TG-1101 in Patients with Neuromyelitis Optica (NMO) presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Ticker: TGTX
Occurred on: Sep 16, 2016
TG Therapeutics Announces Orphan Drug Designation for TG-1101 for the Treatment of Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder
Ticker: TGTX
Occurred on: Aug 26, 2016

Strategic Initiatives (TGTX)

TG Therapeutics (TGTX) and Novimmune Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody
Ticker: TGTX
Announcement Date: Jun 20, 2018

TGTX Overview